G-10

STING agonist-1 (G10) is a human-specific agent that elicits antiviral activity against emerging Alphaviruses.

ZG-10 (JNK-IN-2) is an inhibitor of JNK, blocking JNK1, JNK2, and JNK3, and is used in studies of SARS-CoV-2 virus infection.

KMG-104 is a selective Mg2+ fluorescent probe for dynamic observation of Mg2+ in the cytoplasm of living cells.

LG-100064 is an agonist of retinoid-X-receptor (RXR)(EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ)

Org-10490 is an dopamine D1 receptor and dopamine D2 receptor antagonist, and treatment for psychiatric disease.

S1g-10 is an Hsp70/Bim inhibitor that exhibits significant antitumor activity, particularly in chronic myeloid leukemia (CML) cells. It inhibits the protein-protein interaction between Hsp70 and Bim, blocking cancer cell survival signals and inducing apoptosis. S1g-10 is an optimized derivative of S1g-2, with a 10-fold increase in anticancer potency.

TG-100435 is a novel multi-target oral protein tyrosine kinase inhibitor. The metabolic flux of TG100435 is entirely inhibited by methimazole and ketoconazole. In human liver microsomes or recombinant P450, the formation of TG100435 increases with the activity of cytochrome P450 reductase, suggesting that cytochrome P450 reductase may be involved.

KMG-1068 (Compound 4a), a molecular glue, acts as a GSPT1/2 degrader. By binding to the IMiD binding site on CRBN, KMG-1068 efficiently induces CRBN-dependent degradation of GSPT1/2 and facilitates the formation of a ternary complex with GSPT1/2. KMG-1068 holds potential for use in cancer research.

CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).

RG-102240 is a ligand for the insect ecdysone receptor (EcR). Its IC50 values against wild-type G:CfE (DEF) and A110P mutant are 85 nM and 13 nM, respectively. It activates reporter gene expression of both wild-type CfEcR and the A110P mutant.

Gel filtration medium G-100, a substance designed for protein purification, enables the separation and purification of proteins through gel filtration.

TC-G-1008 (GPR39-C3) is a zinc receptor agonist with EC50 values of 0.4 nM for rat GPR39 and 0.8 nM for human GPR39.

MG-101 (Calpain inhibitor I) is a cell-permeable and potent inhibitor of cysteine proteases including calpains and lysosomal cathepsins.

IG-105 is a potent microtubule inhibitor with potential anticancer activity. IG-105 inhibits microtubule assembly by binding at colchicine pocket. IG-105 shows a potent anticancer activity in vitro and in vivo and has good safety in mice. IG-105 showed a potent activity against human leukemia and solid tumors in breast, liver, prostate, lung, skin, colon, and pancreas with IC(50) values between 0.012 and 0.298 mumol/L. It was also active in drug-resistant tumor cells and not a P-glycoprotein substrate. It inhibited microtubule assembly followed by M-phase arrest, Bcl-2 inactivation, and then apoptosis through caspase pathways.

IAG-10 is a Novel potent and selective inhibitor of human DNA polymerase kappa (hpol κ).

G-1026 is a biochemical that inhibits fumarate reductase activity.

HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).

AG-10 (Acoramidis) is an orally active and selective kinetic stabilizer of TTR (transthyretin). AG-10 exhibits activity for WT and V122I-TTR. AG-10 is used in the study of transthyretin amyloidosis.

PLG-101 is an antibody targeting CD8 and can be used for immunology research.

ADG-106 is a fully human monoclonal antibody targeting CD137 (4-1BB). It activates CD137 via potent FcγRIIB-mediated cross-linking, antagonising CD137 ligands, and may be employed for anti-tumour immunotherapy.

Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.

TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively).

TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).

GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM, respectively.